Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Clinical Trial of of VAR 200 (2-hydroxypropyl-ß-cyclodextrin, or HPßCD) in Adult Patients with Focal Segmental Glomerulosclerosis (FSGS)

Trial Profile

A Phase 2a Clinical Trial of of VAR 200 (2-hydroxypropyl-ß-cyclodextrin, or HPßCD) in Adult Patients with Focal Segmental Glomerulosclerosis (FSGS)

Planning
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Hydroxypropyl betadex (Primary)
  • Indications Focal segmental glomerulosclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Dec 2018 According to a Variant Pharmaceuticals media release, the company has secured $10 Million in financing from Korean company, Incon, in exchange for equity ownership. The funding will be used for the execution of this trial.
    • 24 Oct 2018 New trial record
    • 10 Oct 2018 According to a Variant Corporate presentation (Q4-2018), the dose and proposed clinical endpoints for this trial are acceptable by the FDA.The IND filing is expected in late Q1-2019 and the trial is anticipated to start in Q2-2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top